RESUMEN
BACKGROUND: Chemical plaque control with mouthwashes as an adjunct to mechanical plaque control with a toothbrush and dental floss has been considered an effective method for controlling gingivitis. The anti-inflammatory effects of chemical plaque control benefit the oral tissues by reducing inflammation and bleeding. OBJECTIVES: The aim of the present study was to evaluate and compare the clinical efficacy of probiotic, Aloe vera, povidine-iodine, and chlorhexidine (CHX) mouthwashes in treating gingivitis patients by assessing changes in their clinical parameters. MATERIAL AND METHODS: This prospective study was conducted on 40 patients from our outpatient department, divided into 4 groups of 10 patients each: probiotic mouthwash group (group 1); herbal (Aloe vera) mouthwash group (group 2); povidone-iodine mouthwash group (group 3); and CHX mouthwash group (group 4). All participants were provided with the same type of manual toothbrush, the Pepsodent® toothpaste and a respective mouthwash for twice-daily use until the end of a 28-day observation period. Clinical parameters, such as the marginal plaque index (MPI) and bleeding on interdental brushing (BOIB), were recorded at baseline, and on the 14th and 28th day of the study period. RESULTS: All groups showed a significant decrease in the MPI and BOIB scores. The results were similar in patients who used a probiotic mouthwash and those who used a CHX mouthwash. A comparable change in the mean scores was observed among the herbal and povidone-iodine groups from baseline to day 28. CONCLUSIONS: In the treatment of chronic gingivitis patients,a probiotic mouthwash was nearly as effective as CHX in reducing the plaque and bleeding scores. It showed better results in all clinical parameters than herbal and povidone-iodine mouthwashes. Using a mouthwash along with routine tooth brushing can help in treating gingivitis and slow the progression of the periodontal disease.
Asunto(s)
Aloe , Clorhexidina , Gingivitis , Antisépticos Bucales , Povidona Yodada , Probióticos , Humanos , Gingivitis/tratamiento farmacológico , Gingivitis/terapia , Gingivitis/prevención & control , Antisépticos Bucales/uso terapéutico , Probióticos/uso terapéutico , Clorhexidina/uso terapéutico , Clorhexidina/administración & dosificación , Femenino , Adulto , Masculino , Estudios Prospectivos , Povidona Yodada/administración & dosificación , Povidona Yodada/uso terapéutico , Persona de Mediana Edad , Adulto Joven , Índice Periodontal , Resultado del Tratamiento , Antiinfecciosos Locales/uso terapéutico , Antiinfecciosos Locales/administración & dosificación , Índice de Placa Dental , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Preparaciones de Plantas/administración & dosificaciónRESUMEN
OBJECTIVES: 1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive patients. 2- To determine the salivary cytokine profiles of IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL- 17 among COVID-19 patients subjected to 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline or Neem extract (Azardirachta indica) based gargles. TRIAL DESIGN: This will be a parallel group, quadruple blind-randomised controlled pilot trial with an add on laboratory based study. PARTICIPANTS: A non-probability, purposive sampling technique will be followed to identify participants for this study. The clinical trial will be carried out at the Aga Khan University Hospital (AKUH), Karachi, Pakistan. The viral PCR tests will be done at main AKUH clinical laboratories whereas the immunological tests (cytokine analysis) will be done at the Juma research laboratory of AKUH. The inclusion criteria are laboratory-confirmed COVID-19 positive patients, male or female, in the age range of 18-65 years, with mild to moderate disease, already admitted to the AKUH. Subjects with low Glasgow coma score, with a history of radiotherapy or chemotherapy, who are more than 7 days past the onset of COVID- 19 symptoms, or intubated or edentulous patients will be excluded. Patients who are being treated with any form of oral or parenteral antiviral therapy will be excluded, as well as patients with known pre-existing chronic mucosal lesions such as lichen planus. INTERVENTION AND COMPARATOR: Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.) for 20-30 seconds, thrice daily for 6 days. Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.) for 20-30 seconds, thrice daily for 6 days. Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated by Karachi University (chemistry department laboratories) for 20-30 seconds, thrice daily for 6 days. Group D (n=10) patients will use 2% hypertonic saline (Plabottle® by Otsuka Inc.) gargle and nasal lavage for a similar time period. Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days. For nasal lavage, a special douche syringe will be provided to each participant. Its use will be thoroughly explained by the data collection officer. After each use, the patient is asked not to eat, drink, or rinse their mouth for the next 30 minutes. MAIN OUTCOMES: The primary outcome is the reduction in the intra-oral viral load confirmed with real time quantitative PCR. RANDOMISATION: The assignment to the study group/ allocation will be done using the sealed envelope method under the supervision of Clinical Trial Unit (CTU) of Aga Khan University, Karachi, Pakistan. The patients will be randomised to their respective study group (1:1:1:1:1 allocation ratio) immediately after the eligibility assessment and consent administration is done. BLINDING (MASKING): The study will be quadruple-blinded. Patients, intervention provider, outcome assessor and the data collection officer will be blinded. The groups will be labelled as A, B, C, D or E. The codes of the intervention will be kept in lock & key at the CTU and will only be revealed at the end of study or if the study is terminated prematurely. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. The present study will serve as a pilot trial. We intend to study 50 patients in five study groups with 10 patients in each study group. For details, please refer to Fig. 1 for details. TRIAL STATUS: Protocol version is 7.0, approved by the department and institutional ethics committees and clinical trial unit of the university hospital. Recruitment is planned to start as soon as the funding is sanctioned. The total duration of the study is expected to be 6 months i.e. August 2020-January 2021. TRIAL REGISTRATION: This study protocol was registered at www.clinicaltrials.gov on 10 April 2020 NCT04341688 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). Fig. 1 Flow diagram of study-participants' timeline.
Asunto(s)
Azadirachta , Betacoronavirus , Infecciones por Coronavirus , Peróxido de Hidrógeno/administración & dosificación , Pandemias , Extractos Vegetales/administración & dosificación , Neumonía Viral , Povidona Yodada/administración & dosificación , Solución Salina Hipertónica/administración & dosificación , Carga Viral , Adulto , Antiinfecciosos Locales/administración & dosificación , Betacoronavirus/efectos de los fármacos , Betacoronavirus/aislamiento & purificación , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/terapia , Femenino , Hospitalización , Humanos , Masculino , Monitorización Inmunológica/métodos , Antisépticos Bucales/administración & dosificación , Lavado Nasal (Proceso)/métodos , Neumonía Viral/diagnóstico , Neumonía Viral/inmunología , Neumonía Viral/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2 , Carga Viral/efectos de los fármacos , Carga Viral/métodosRESUMEN
PURPOSE: To report safety and tolerability of a one-time administration of ophthalmic 5% povidone-iodine (5% PVP-I) in a double-masked randomized trial for the treatment of adenoviral conjunctivitis (Ad-Cs). METHODS: Of 212 participants screened, 56 eligible participants with red eye symptoms ≤4 days and a positive adenoviral rapid immunoassay were randomized to a one-time administration of ophthalmic 5% PVP-I or preservative free artificial tears (AT). Safety was assessed by corneal fluorescein staining (baseline, immediate post-administration and Day 1) and visual acuity (VA) (baseline and Day 1). Tolerability was assessed using participant-rated overall ocular discomfort (baseline, immediately post-administration and on Day 1. RESULTS: In the 5% PVP-I group, corneal staining increased immediately post-administration but returned to baseline levels by Day 1. There was no change in VA between baseline and Day 1 in either 5% PVP-I or AT groups (pâ¯=â¯0.87). In the 5% PVP-I group, there was no change in participant-rated overall discomfort immediately post-administration (pâ¯=â¯0.78) or on day 1 (pâ¯=â¯0.10) compared to baseline. In the AT group, participant-rated overall discomfort was lower immediately post-administration but returned to baseline levels by Day 1. One adverse event was reported in the 5% PVP-I group on Day 1-2 that was classified as not related to treatment. CONCLUSION: These results suggest ophthalmic 5% PVP-I used as a one-time treatment is safe and well tolerated by patients with Ad-Cs.
Asunto(s)
Infecciones por Adenoviridae/tratamiento farmacológico , Conjuntivitis/tratamiento farmacológico , Infecciones Virales del Ojo/tratamiento farmacológico , Gotas Lubricantes para Ojos , Povidona Yodada/administración & dosificación , Agudeza Visual , Adulto , Conjuntivitis/virología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Masculino , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVES: To investigate a way to reduce infectious complication after transrectal ultrasonography-guided prostate biopsy (TRUS-Bx), we planned a randomized trial to determine whether the use of the povidone-iodine suppository is effective in preventing infectious complications. METHODS: This study prospectively assessed 250 patients who underwent TRUS-Bx during December 2014 and May 2016. Clinical questionnaire responses and safety were evaluated. Povidone-iodine suppository after glycerin enema was performed 1 to 2âhours before TRUS-Bx. Both groups received the prophylactic antibiotics (ceftriaxone 2.0âg) 30 to 60 minutes before TRUS-Bx. No antibiotics were prescribed after TRUS-Bx. RESULTS: The 120 were assigned in the treatment group using povidone-iodine suppository and 130 were assigned in the control group. There was no significant difference of clinicopathologic features including age, prostate-specific antigen and cancer detection rate in both groups (Pâ>â.05). No infectious and non-infectious complications were reported in both groups. Povidone-iodine suppository-related side effects were not reported. No significant differences in international prostate symptom score, sexual health inventory for men score, and European Organization for Research and Treatment of Cancer Quality of Life questionnaire scores were found between the 2 groups (Pâ>â.05). No changes in each questionnaire scores between before and after TRUS-Bx were observed. CONCLUSIONS: Despite satisfying the predefined sample size, we could not prove the hypothesis that the use of povidone-iodine suppositories after TRUS-Bx would reduce infectious complications. A large-scale, multicenter, prospective study is needed to fully evaluate the clinical efficacy and safety of povidone-iodine suppository prior to TRUS-Bx.
Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Profilaxis Antibiótica/métodos , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico/métodos , Povidona Yodada/administración & dosificación , Próstata/patología , Anciano , Antiinfecciosos Locales/efectos adversos , Ceftriaxona/administración & dosificación , Ceftriaxona/efectos adversos , Quimioterapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Povidona Yodada/efectos adversos , Estudios Prospectivos , SupositoriosRESUMEN
CONTEXT: Prostate biopsy is one of the most performed procedures in urology. As a diagnostic procedure it should be of low risk. However, morbidity following prostate biopsy is common due to infectious complications. OBJECTIVE: To describe how to reduce infectious complications following prostate biopsy. We report on antibiotic and technical interventions to reduce infectious complications. EVIDENCE ACQUISITION: The data presented are based on a narrative review. Search in PubMed and Medline was performed until May 2018 with a focus on randomised controlled trials and meta-analyses. Articles were reviewed for data on symptomatic infections, hospitalisation, and adverse events. EVIDENCE SYNTHESIS: Antibiotic prophylaxis is the standard of care. However, the duration of antibiotic preemptive treatment is still under debate. The use of augmented antibiotic prophylaxis as well as targeted antibiotic prophylaxis might be of potential value, but evidence is currently limited. Moreover, no antibiotic class was shown to be clearly superior to another. The evaluation of the technical aspects during prostate biopsy reveals that rectal preparation with povidone-iodine is clearly effective to reduce infectious complications. Transperineal biopsy has a potential benefit to reduce infectious complications, but powerful randomised controlled studies are missing. Finally, the number of biopsy cores, the application of periprostatic nerve block, or the use of a cleansing enema has no impact on prostate biopsy in terms of infectious complications. CONCLUSIONS: The available data only suggest that rectal preparation with povidone-iodine as well as antibiotic prophylaxis is of significant advantage to reduce infectious complications following prostate biopsy. The augmented and targeted antibiotic prophylaxis shows some potential, but need further validation. PATIENT SUMMARY: In this review we evaluate the best management strategy to prevent infectious complications following prostate biopsy. We show that antibiotic prophylaxis is essential for prostate biopsy and that rectal preparation with povidone-iodine is mandatory.
Asunto(s)
Infecciones Bacterianas/prevención & control , Biopsia/efectos adversos , Povidona Yodada/administración & dosificación , Próstata/microbiología , Administración Rectal , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/tratamiento farmacológico , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Metaanálisis como Asunto , Povidona Yodada/uso terapéutico , Próstata/patología , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Infectious ocular disease, such as conjunctivitis, is common in cats and can be caused by several viruses and bacteria, either as a single infection or as co-infections. In this study, povidone-iodine (PVP-I), alone or compounded with hydroxyethyl cellulose (HEC), was investigated for its efficacy against these pathogens in vitro. Whilst PVP-I alone was effective at inhibiting feline herpesvirus type 1 (FHV-1), Chlamydia felis, and Mycoplasma felis, PVP-I with HEC exerted a synergistic inhibitory effect against FHV-1 and C. felis. In contrast, only minimal inhibition of feline calicivirus was observed. These results demonstrate that PVP-I, alone and in combination with HEC, is effective against some feline ocular pathogens when tested in cell lines in vitro. In vivo studies investigating the systemic safety, ocular tolerance, and clinical efficacy of this combination in cats would be necessary before it could be recommended as a therapy in affected cats.
Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Enfermedades de los Gatos/tratamiento farmacológico , Celulosa/análogos & derivados , Conjuntivitis/veterinaria , Soluciones Oftálmicas/uso terapéutico , Povidona Yodada/uso terapéutico , Animales , Antiinfecciosos Locales/administración & dosificación , Antiinfecciosos Locales/farmacología , Calicivirus Felino/efectos de los fármacos , Enfermedades de los Gatos/microbiología , Gatos , Celulosa/administración & dosificación , Celulosa/uso terapéutico , Chlamydia/efectos de los fármacos , Infecciones por Chlamydophila/tratamiento farmacológico , Infecciones por Chlamydophila/veterinaria , Conjuntivitis/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Infecciones por Herpesviridae/tratamiento farmacológico , Infecciones por Herpesviridae/veterinaria , Masculino , Pruebas de Sensibilidad Microbiana/veterinaria , Mycoplasma/efectos de los fármacos , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/veterinaria , Soluciones Oftálmicas/administración & dosificación , Povidona Yodada/administración & dosificación , Povidona Yodada/farmacología , Resultado del TratamientoRESUMEN
Abstract Introduction Otomycosis is a common diseases that can be associated with many complications including involvement of the inner ear and mortality in rare cases. Management of otomycosis can be challenging, and requires a close follow-up. Treatment options for otomycosis include local debridement, local and systemic antifungal agents and utilization of topical antiseptics. Objective This study was designed to compare the recovery rate of otomycosis using two therapeutic methods; topical betadine (Povidone-iodine) and clotrimazole. Methods In this single-blind clinical trial, 204 patients with otomycosis were selected using a non-probability convenient sampling method and were randomly assigned to two treatment groups of topical betadine and clotrimazole (102 patients in each group). Response to treatment was assessed at 4, 10 and 20 days after treatment. Data were analyzed using the independent t-test, Chi-Square and Fisher exact test in SPSS v.18 software, at a significance level of p < 0.05. Results The results showed that out of 204 patients with otomycosis, fungi type isolated included Aspergillus in 151 cases (74%), and Candida albicans in 53 patients (26%). On the fourth day after treatment, 13 patients (13.1%) in the group treated with betadine and 10 patients (9.8%) in the group treated with clotrimazole showed a good clinical response to treatment (p = 0.75). A good response to treatment was reported for 44 (43.1%) and 47 patients (46.1%) on the tenth day after the treatment (p = 0.85); and 70 (68.6%) and 68 patients (67.6%) on the twentieth day after treatment (p = 0.46) in the groups treated with betadine and clotrimazole, respectively. The response to treatment was thus not significantly different in the two groups. Conclusion In the present study the efficacy of betadine and clotrimazole was the same for the treatment of otomycosis. The result of this study supports the use of betadine as an effective antifungal in otomycosis treatment, helping to avoid the emergence of resistant organisms.
Resumo Introdução A otomicose é uma das doenças comuns associadas a muitas complicações, como envolvimento da orelha interna e mortalidade em casos raros. O tratamento da otomicose pode ser realmente desafiador e requer um acompanhamento rigoroso. As opções de tratamento para otomicose podem incluir desbridamento local, agentes antifúngicos locais e sistêmicos e uso de antissépticos tópicos, os medicamentos tópicos recomendados para o tratamento da otomicose. Objetivo Comparar a taxa de recuperação de otomicose utilizando dois métodos terapêuticos de betadina tópica (povidona-iodo) e clotrimazol. Método Neste ensaio clínico simples cego, 204 pacientes com otomicose foram selecionados utilizando-se método de amostragem de não probabilidade conveniente e randomizados para dois grupos de tratamento, com betadina tópica e com clotrimazol (102 pacientes em cada grupo). A resposta ao tratamento foi avaliada aos 4, 10 e 20 dias após o tratamento. Os dados foram analisados utilizando o teste t independente, qui-quadrado e teste de Fisher no software SPSS v.18, com nível de significância de p < 0,05. Resultados Os resultados mostraram que dos 204 pacientes com otomicose, os tipos de fungos isolados incluíram Aspergillus em 151 casos (74%) e Candida albicans em 53 pacientes (26%). No quarto dia após o tratamento, 13 pacientes (13,1%) no grupo tratado com betadina e 10 pacientes (9,8%) no grupo tratado com clotrimazol apresentaram boa resposta ao tratamento (p = 0,75). Uma boa resposta ao tratamento foi relatada para 44 (43,1%) e 47 pacientes (46,1%) no décimo dia após o tratamento (p = 0,85); e 70 (68,6%) e 68 pacientes (67,6%) no vigésimo dia após o tratamento (p = 0,46) no grupo tratado com betadina e clotrimazol, respectivamente. Assim, a resposta ao tratamento não foi significativamente diferente nos dois grupos. Conclusão No presente estudo, a eficácia da betadina e do clotrimazol foi a mesma no tratamento da otomicose. O resultado deste estudo apoia o uso de betadina como um antifúngico eficaz no tratamento da otomicose que pode ajudar a evitar o surgimento de organismos resistentes.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Adulto Joven , Povidona Yodada/administración & dosificación , Clotrimazol/administración & dosificación , Otomicosis/tratamiento farmacológico , Antiinfecciosos Locales/administración & dosificación , Antifúngicos/administración & dosificación , Aspergillus/aislamiento & purificación , Factores de Tiempo , Administración Cutánea , Candida albicans/aislamiento & purificación , Método Simple Ciego , Reproducibilidad de los Resultados , Resultado del TratamientoRESUMEN
PURPOSE: Medical implants and surgical site infections (SSIs) can be a burden on both patients and healthcare systems with a significant rise in morbidity, mortality and costs. Preoperatively, our practice of a chlorohexidine gluconate (CHG) washcloth bath or solution shower was supplemented with nasal painting using povidone-iodine skin and nasal antiseptic (PI-SNA). We sought to measure the effectiveness in reducing SSIs in patients undergoing repair of lower extremity fractures. METHODS: A retrospective review of trauma patients undergoing orthopedic operations conducted at Conemaugh Memorial Medical Center from 10/1/2012 through 9/30/2016. The intervention period was 10/1/2014 to 9/30/2016 which included the addition of nasal painting with PI-SNA preoperatively. All patients were followed for 1 year prior to January 2013 and 30 or 90 days thereafter for the development of a SSI. RESULTS: The pre-intervention group consisted of 930 cases with a 1.1% infection rate (10 SSIs). The intervention group consisted of 962 cases with a 0.2% infection rate (2 SSIs). This observed difference was statistically significant (P = 0.020). CONCLUSIONS: This retrospective review of a methicillin-resistant Staphylococcus aureus decolonization protocol using CHG bath/shower and PI-SNA nasal painting revealed a significant decrease in the infection rate of patients undergoing lower extremity fracture repairs. We recommend its use without contraindications, but recognize that additional investigations are necessary.
Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Clorhexidina/administración & dosificación , Traumatismos de la Pierna/cirugía , Povidona Yodada/administración & dosificación , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/prevención & control , Infección de la Herida Quirúrgica/microbiología , Infección de la Herida Quirúrgica/prevención & control , Administración Intranasal , Adulto , Anciano , Baños , Portador Sano/tratamiento farmacológico , Femenino , Humanos , Masculino , Staphylococcus aureus Resistente a Meticilina , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
INTRODUCTION: Otomycosis is a common diseases that can be associated with many complications including involvement of the inner ear and mortality in rare cases. Management of otomycosis can be challenging, and requires a close follow-up. Treatment options for otomycosis include local debridement, local and systemic antifungal agents and utilization of topical antiseptics. OBJECTIVE: This study was designed to compare the recovery rate of otomycosis using two therapeutic methods; topical betadine (Povidone-iodine) and clotrimazole. METHODS: In this single-blind clinical trial, 204 patients with otomycosis were selected using a non-probability convenient sampling method and were randomly assigned to two treatment groups of topical betadine and clotrimazole (102 patients in each group). Response to treatment was assessed at 4, 10 and 20 days after treatment. Data were analyzed using the independent t-test, Chi-Square and Fisher exact test in SPSS v.18 software, at a significance level of p<0.05. RESULTS: The results showed that out of 204 patients with otomycosis, fungi type isolated included Aspergillus in 151 cases (74%), and Candida albicans in 53 patients (26%). On the fourth day after treatment, 13 patients (13.1%) in the group treated with betadine and 10 patients (9.8%) in the group treated with clotrimazole showed a good clinical response to treatment (p=0.75). A good response to treatment was reported for 44 (43.1%) and 47 patients (46.1%) on the tenth day after the treatment (p=0.85); and 70 (68.6%) and 68 patients (67.6%) on the twentieth day after treatment (p=0.46) in the groups treated with betadine and clotrimazole, respectively. The response to treatment was thus not significantly different in the two groups. CONCLUSION: In the present study the efficacy of betadine and clotrimazole was the same for the treatment of otomycosis. The result of this study supports the use of betadine as an effective antifungal in otomycosis treatment, helping to avoid the emergence of resistant organisms.
Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Antifúngicos/administración & dosificación , Clotrimazol/administración & dosificación , Otomicosis/tratamiento farmacológico , Povidona Yodada/administración & dosificación , Administración Cutánea , Adulto , Aspergillus/aislamiento & purificación , Candida albicans/aislamiento & purificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Método Simple Ciego , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE: The aim of this study was to evaluate the effect of povidone-iodine rectal disinfection and targeted antimicrobial prophylaxis in men undergoing transrectal ultrasound-guided prostate biopsy based on rectal swab culture results. METHODS: From January 2011 to December 2015, we studied differences in infectious complications in men who received povidone-iodine rectal disinfection with targeted antimicrobial prophylaxis and those who received empirical prophylaxis before transrectal ultrasound-guided prostate biopsy. Clinical variables including demographics, prior antibiotic, rectal swab culture results, povidone-iodine rectal cleansing, antibiotic prophylaxis, and infectious complications were evaluated. Patients were divided into three groups as follows: Group A received no povidone-iodine rectal cleansing but received empirical antimicrobial prophylaxis; group B received povidone-iodine rectal cleansing and empirical antimicrobial prophylaxis; and group C received povidone-iodine rectal cleansing and targeted antimicrobial prophylaxis. RESULTS: Patients were divided into group A (n = 192; 13.2 %), group B (n = 579; 39.9 %), or group C (n = 679; 46.8 %). In groups A and B, all patients received fluoroquinolone antimicrobial prophylaxis. Group C patients received targeted antimicrobial prophylaxis according to antibiotic resistance of rectal flora, and 71.1 % of these received fluoroquinolone antimicrobial prophylaxis. Infectious complication rates were 3.6, 2.9, and 1.3 % in group A, group B, and group C, respectively. Incidences of acute prostatitis and bacteremia were significantly lower in group C (p = 0.041 and p = 0.049, respectively) than in the other groups. CONCLUSIONS: In the era of quinolone resistance, the combination of povidone-iodine rectal cleansing and targeted antibiotic prophylaxis may reduce the rate of infectious complications.
Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos Locales/administración & dosificación , Profilaxis Antibiótica/métodos , Infecciones Bacterianas/prevención & control , Fluoroquinolonas/uso terapéutico , Povidona Yodada/administración & dosificación , Recto/microbiología , Anciano , Infecciones Bacterianas/etiología , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico/efectos adversos , Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico/métodos , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Próstata/patología , Prostatitis/etiología , Prostatitis/prevención & controlRESUMEN
PURPOSE: To evaluate the effect of povidone iodine and hydrogen peroxide on fracture healing in a rat model. METHODS: The middle section of the right femur of 36 male Sprague Dawley rats was osteotomised with a saw. In the control group (n=9), the wound was irrigated with 100 ml 0.9% saline. In the 10% povidone iodine (n=9), 1% povidone iodine (n=9), and 3% hydrogen peroxide (n=9) groups, the wound was completely soaked with the respective solution for 2 minutes, and then irrigated with 100 ml saline. The osteotomy was fixed with an intramedullary Kirschner wire. Rats were euthanised at week 1, 2, and 5. In each femur, the percentage area of osseous, cartilaginous, and fibrous tissue in the callus was evaluated in 3 slides (one median and 2 paramedian). RESULTS: The control group differed significantly to the other 3 groups (p=0.023 to p<0.001) in weeks 1, 2, and 5, except for the 1% povidone iodine group in terms of percentage of osseous (p=0.349) and fibrous (p=0.999) tissue. The healing process was similar in the 1% povidone iodine group and the control group, whereas healing was impaired in the 10% povidone iodine group and 3% hydrogen peroxide group, as indicated by the lower percentage of osseous tissue, higher percentage of fibrous tissue, and increased percentage of cartilaginous tissue between weeks 2 and 5 (delayed bone healing). CONCLUSION: The 1% povidone iodine solution is recommended as the irrigation adjuvant in fracture surgery.
Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Fémur/fisiopatología , Curación de Fractura/efectos de los fármacos , Peróxido de Hidrógeno/administración & dosificación , Povidona Yodada/administración & dosificación , Animales , Modelos Animales de Enfermedad , Fémur/efectos de los fármacos , Fémur/cirugía , Masculino , Osteotomía , Ratas , Ratas Sprague-Dawley , Cicatrización de Heridas/efectos de los fármacosRESUMEN
PURPOSE: To investigate the bactericidal effect of 0.025% povidone-iodine in Balanced Salt Solution PLUS (0.025% PI-BSS PLUS) and its use in vitrectomy for postoperative endophthalmitis. METHODS: First, an experimental laboratory model using Staphylococcus aureus was used to evaluate the bactericidal effect of PI-BSS PLUS. Next, in a case series of 4 eyes with postoperative endophthalmitis, vitrectomy using 0.025% PI-BSS PLUS as irrigation solution was conducted, followed by postoperative intravitreal and intravenous antibiotics. RESULTS: In in vitro study, PI at concentrations of 0.01% and above in BSS PLUS exhibited marked bactericidal effect after 15 seconds of exposure. Bactericidal effect of 0.025% PI-BSS PLUS was maintained at room temperature storage for 15 minutes but was attenuated after 30 minutes. Among 4 eyes that underwent vitrectomy using 0.025% PI-BSS PLUS, coagulase-negative Staphylococcus sp. was isolated in 1 eye at the beginning but not at completion of surgery. In all four eyes, endophthalmitis was resolved with no adverse events. Ocular toxicity was not observed. CONCLUSION: The 0.025% PI-BSS PLUS is bactericidal and nontoxic when used as irrigation solution in vitrectomy. In 4 cases of postoperative endophthalmitis, vitrectomy using 0.025% PI-BSS PLUS followed by postoperative antibiotics resolved endophthalmitis.
Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Bicarbonatos/administración & dosificación , Endoftalmitis/terapia , Infecciones Bacterianas del Ojo/terapia , Glutatión/administración & dosificación , Povidona Yodada/administración & dosificación , Infecciones Estafilocócicas/terapia , Vitrectomía , Adulto , Anciano , Anciano de 80 o más Años , Recuento de Colonia Microbiana , Terapia Combinada , Combinación de Medicamentos , Endoftalmitis/tratamiento farmacológico , Endoftalmitis/etiología , Endoftalmitis/cirugía , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Infecciones Bacterianas del Ojo/etiología , Infecciones Bacterianas del Ojo/cirugía , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Complicaciones Posoperatorias , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/etiología , Infecciones Estafilocócicas/cirugía , Staphylococcus aureus/efectos de los fármacos , Irrigación TerapéuticaRESUMEN
PURPOSE: To evaluate the risk factors and efficacy of a povidone-iodine enema on infectious complications after transrectal ultrasound-guided prostate biopsy. METHODS: A total of 814 males who underwent transrectal ultrasound-guided prostate biopsy from January 2011 to December 2013 were evaluated retrospectively. Clinical variables, including demographics, prior antibiotic, or quinolone exposure, rectal swab culture results, povidone-iodine rectal cleansing, antibiotic prophylaxis, and infectious complications, were evaluated. RESULTS: Overall, 16 of 814 (2.0%) patients developed infectious complications after prostate biopsy. Of the patients with infectious complications, five had fever, two had urinary tract infections, and nine had bacteremia or sepsis. Infectious complication rates were not significantly different between povidone-iodine rectal cleansing (n = 613) and no cleansing (n = 201) groups (1.5 vs. 3.5%, p = 0.083). However, povidone-iodine rectal cleansing reduced severe infectious complications such as bacteremia and sepsis (0.3 vs. 3.5%, p = 0.001). A rectal swab culture was performed in 552 patients, and extended-spectrum ß-lactamase (ESBL)-producing and quinolone-resistant Escherichia coli were detected in 4.5 and 7.8% of cultures, respectively. Quinolone and antibiotic exposure within 6 months prior to prostate biopsy were associated with quinolone resistance and ESBL positivity of rectal flora and infectious complications. CONCLUSIONS: In the era of quinolone resistance, a povidone-iodine enema may reduce the infectious complication rate by reducing bacterial load. Quinolone exposure prior to prostate biopsy was a risk factor for antibiotic resistance to rectal flora and infectious complications.
Asunto(s)
Infecciones Bacterianas/prevención & control , Biopsia con Aguja/métodos , Biopsia Guiada por Imagen , Povidona Yodada/administración & dosificación , Próstata/patología , Enfermedades de la Próstata/diagnóstico , Ultrasonografía Intervencional/métodos , Administración Rectal , Adulto , Anciano , Anciano de 80 o más Años , Antiinfecciosos Locales/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Irrigación Terapéutica/métodosRESUMEN
BACKGROUND: To describe a preparatory protocol for prostate biopsy consisting of prophylaxis based on a third-generation cephalosporin and suppository-type povidone-iodine. METHODS: From January 2004 to May 2012 we reviewed infective complications in 1,684 patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy. All of the patients received prophylactic antibiotics through a single intravenous injection of a third-generation cephalosporin and cefixime at 100 mg PO for 5 d, with this regimen begun before biopsy, and were also given gynobetadine in a dose of 200 mg just before biopsy. Infectious complications were classified as sepsis, fever (>38°C) without sepsis, and other clinical manifestations of infection. To evaluate the bactericidal effects of gynobetadine, we counted bacterial colonies prospectively in cultures of rectal swab specimens from 150 patients who underwent TRUS-guided prostate biopsy. RESULTS: Complications occurred in 46 of the patients (2.73%), including infective complications in 11 (0.65%) patients and non-infective complications in 35 (2.08%) patients. Of the patients with infective complications, two had fever without sepsis, none had clinical urinary tract infections without fever, and none had sepsis. In prospective in vitro investigations, the mean bacterial colony count before rectal preparation with an enema or rectal insertion of povidone-iodine suppository was 2.38×10(6), whereas the colony count after a povidone-iodine rectal enema and subsequent biopsy was 1.81×10(3) and the colony count after rectal preparation with povidone-iodine suppository and subsequent biopsy was 8.1×10(2) (all p<0.001). CONCLUSIONS: The administration of cephalosporin-based prophylactic antibiotics and the simple use of suppository-type povidone-iodine provided an excellent protocol for reducing infective complications of TRUS-guided prostate biopsy. The simplicity of use and cost effectiveness of gynobetadine were noteworthy.
Asunto(s)
Antibacterianos/administración & dosificación , Infecciones Bacterianas/prevención & control , Biopsia con Aguja/efectos adversos , Biopsia con Aguja/métodos , Quimioprevención/métodos , Enfermedades de la Próstata/diagnóstico , Enfermedades de la Próstata/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Cefalosporinas/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Povidona Yodada/administración & dosificación , Cuidados Preoperatorios/métodos , Estudios Retrospectivos , Temperatura , Resultado del TratamientoRESUMEN
PURPOSE: Radiation-induced oral mucositis is an acute morbidity seen in patients undergoing treatment for head and neck cancers. In this study, we evaluated the efficacy of turmeric in preventing radiation-induced mucositis. METHODS: This was a single-blinded, randomized, controlled clinical trial and was conducted with head and neck cancer patients requiring 70 Gy of radiation or chemoradiotherapy (daily radiotherapy plus carboplatin once a week). Eligible patients (n = 80) were randomly assigned to receive either turmeric gargle (n = 40) or povidone-iodine ([n = 40] active comparator condition) during chemo/radiotherapy during the period of treatment. Oral mucositis was assessed using the RTOG (Radiation Therapy Oncology Group) grading system before the start, during, and at the end of the treatment by an investigator unaware of the treatment. The primary endpoint of this study was the incidence of mucositis every week during the 7-week period. The secondary endpoint was the effect of turmeric gargle on the incidence of treatment breaks, loss of scheduled treatment days, and decrease in body weight at the end of the treatment. RESULTS: This study clearly suggests that when compared with the cohorts using povidone-iodine gargle, the group using turmeric as a mouthwash had delayed and reduced the levels of radiation-induced oral mucositis and was statistically significant at all time points (P< 0.001 toP< 0.0001). Additionally, the cohorts using turmeric had decreased intolerable mucositis (P< 0.001) and lesser incidence of treatment breaks in the first half of the treatment schedule before 4 weeks (P< 0.01) and reduced change in body weight (P< 0.001). CONCLUSIONS: Gargling with turmeric by head and neck cancer patients undergoing radiation therapy provided significant benefit by delaying and reducing the severity of mucositis. Turmeric is readily available, relatively inexpensive, and highly accepted making it useful in cancer treatment.
Asunto(s)
Curcuma/química , Neoplasias de Cabeza y Cuello/radioterapia , Traumatismos por Radiación/patología , Estomatitis/prevención & control , Adulto , Anciano , Antiinfecciosos Locales/administración & dosificación , Antiinfecciosos Locales/uso terapéutico , Carboplatino/administración & dosificación , Quimioradioterapia/efectos adversos , Quimioradioterapia/métodos , Femenino , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Antisépticos Bucales/administración & dosificación , Povidona Yodada/administración & dosificación , Povidona Yodada/uso terapéutico , Traumatismos por Radiación/epidemiología , Método Simple Ciego , Estomatitis/epidemiología , Estomatitis/etiología , Factores de TiempoRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Pedilanthus tithymaloides leaves are widely used in Indian medicine to heal wounds, burn, mouth ulcers. However, systematic evaluation of these activities is lacking. Thus, the present study aimed to assesses the wound healing activity of Pedilanthus leaves and its isolated constituents in topical ointment formulation. MATERIALS AND METHODS: Bioassay-guided chromatographic fractionation of the methanol extract of leaves resulted in the isolation of 2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-one and 1, 2-tetradecanediol, 1-(hydrogen sulfate), sodium salt. The ointment formulation of methanol extract (2.5%, 5% w/w) and isolated compounds (0.25% w/w) was prepared and evaluated on excision, incision and dead space wound models in rats. The effects of formulations on wound healing were assessed by the rate of wound closure, period of epithelialization, tensile strength, granulation tissue weight, hydroxyproline content and histopathology. RESULTS: Significant wound healing activity was observed with methanol extract and isolated constituents. Topical application of isolated compound ointments caused faster epithelialization, significant wound contraction (95.41%), and better tensile strength (565.33 g) on 16 post-wounding day, while 5% extract showed wound epithelialization with 95.55% contraction on 18th post-wounding day, better than the control group (76.39% on 22 day). The tensile strength of incision wound was significantly increased in extract and compound treated animals. Moreover, in dead space model the extract significantly increased granuloma tissue weight, tensile strength and hydroxyproline content. The tissue histology of ointment treated groups showed complete epithelialization with increased collagenation, compared to the povidone-iodine group. CONCLUSIONS: The results validated the traditional use of Pedilanthus tithymaloides for cutaneous wound management.
Asunto(s)
Antiinfecciosos/administración & dosificación , Euphorbia , Fitoterapia , Extractos Vegetales/administración & dosificación , Cicatrización de Heridas/efectos de los fármacos , Administración Tópica , Animales , Antiinfecciosos/toxicidad , Bacterias/efectos de los fármacos , Candida/efectos de los fármacos , Cryptococcus/efectos de los fármacos , Masculino , Metanol/química , Pruebas de Sensibilidad Microbiana , Pomadas , Extractos Vegetales/toxicidad , Hojas de la Planta/química , Povidona Yodada/administración & dosificación , Ratas , Ratas Wistar , Solventes/químicaRESUMEN
OBJECTIVE: To evaluate the efficacy of a combination anaesthetic plus dilating gel (ADG) on pupil dilation (PD) and corneal anaesthesia (KA) compared to traditional preoperative pharmacotherapy for cataract surgery. DESIGN: Prospective, noninferiority study. METHODS: We studied 20 consenting adults who experienced unilateral cataracts and underwent routine cataract surgery, receiving the traditional preoperative pharmacologic regimen in the operated eye (control eye): diclofenac 0.1%, gentamicin 0.3%, cyclopentolate 1%, phenylephrine 2.5%, and tropicamide 1% 60 and 20 minutes prior to surgery. They then received tetracaine 0.5% and povidone-iodine 5% 10 minutes prior to surgery; and were given tetracaine 0.5%, povidone-iodine 5%, and lidocaine 2% gel 1 minute prior to surgery. Epinephrine 0.1%, 1 cc per 500 mL bag of balanced saline salt solution was administered during surgery. The nonoperated eye (study eye) received tetracaine 0.5%, povidone-iodine 5%, and 0.35 cc ADG gel (phenylephrine 10%, tropicamide 1%, diclofenac 0.1%, and lidocaine 2%) 60 and 10 minutes prior to surgery. PD and KA were measured at baseline, at 30 minutes, and at 5 minutes prior to surgery, and at 5 minutes after surgery. RESULTS: There was no difference in PD (p = 0.2634) or KA (p = 0.6058) between the study eyes and the control eyes at baseline. Preoperatively, greater mydriasis was achieved in the study eye (7.95 ± 0.91 mm vs 7.17 ± 1.25 mm; p < 0.0001). There was no significant difference in preoperative KA between the study and control eyes (1.5 ± 2.2 mm vs 1.4 ± 2.1 mm; p = 0.77). CONCLUSIONS: The combination ADG for preoperative preparation of cataract patients achieves at least equivalent dilation and corneal anaesthesia as the current preoperative pharmacologic regimen.
Asunto(s)
Anestesia Local/métodos , Anestésicos Locales/administración & dosificación , Extracción de Catarata , Midriáticos/administración & dosificación , Pupila/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Córnea/fisiología , Diclofenaco/administración & dosificación , Combinación de Medicamentos , Femenino , Geles , Humanos , Lidocaína/administración & dosificación , Masculino , Persona de Mediana Edad , Fenilefrina/administración & dosificación , Povidona Yodada/administración & dosificación , Estudios Prospectivos , Tetracaína/administración & dosificación , Resultado del Tratamiento , Tropicamida/administración & dosificaciónRESUMEN
BACKGROUND: We did a systematic review and random effects meta-analysis of randomised trials to assess the effect of oral care with chlorhexidine or povidone-iodine on the prevalence of ventilator-associated pneumonia versus oral care without these antiseptics in adults. METHODS: Studies were identified through PubMed, CINAHL, Web of Science, CENTRAL, and complementary manual searches. Eligible studies were randomised trials of mechanically ventilated adult patients receiving oral care with chlorhexidine or povidone-iodine. Relative risks (RR) and 95% CIs were calculated with the Mantel-Haenszel model and heterogeneity was assessed with the I(2) test. FINDINGS: 14 studies were included (2481 patients), 12 investigating the effect of chlorhexidine (2341 patients) and two of povidone-iodine (140 patients). Overall, antiseptic use resulted in a significant risk reduction of ventilator-associated pneumonia (RR 0.67; 95% CI 0.50-0.88; p=0.004). Chlorhexidine application was shown to be effective (RR 0.72; 95% CI 0.55-0.94; p=0.02), whereas the effect resulting from povidone-iodine remains unclear (RR 0.39; 95% CI 0.11-1.36; p=0.14). Heterogeneity was moderate (I(2)=29%; p=0.16) for the trials using chlorhexidine and high (I(2)=67%; p=0.08) for those assessing povidone-iodine use. Favourable effects were more pronounced in subgroup analyses for 2% chlorhexidine (RR 0.53, 95% CI 0.31-0.91), and in cardiosurgical studies (RR 0.41, 95% CI 0.17-0.98). INTERPRETATION: This analysis showed a beneficial effect of oral antiseptic use in prevention of ventilator-associated pneumonia. Clinicians should take these findings into account when providing oral care to intubated patients. FUNDING: None.